Search

Background: Pemphigus vulgaris (PV) is a potentially fatal autoimmune bullous disease primarily caused by acantholysis of keratinocytes attributed to pathogenic desmoglein‐3 (Dsg3) autoantibodies. Interleukin‐37 (IL‐37) reportedly plays important roles in a variety of autoimmune diseases, but its role in PV is not clear. Objectives: To investigate whether IL‐37 plays a role in the occurrence and progression of PV. Methods: HaCaT keratinocytes were stimulated with anti‐Dsg3 antibody to establish an in vitro PV model, which was defined as anti‐Dsg3 group. Cells incubated with medium without anti‐Dsg3 treatment were used as control. IL‐37 was cultured with these cells infected with or without lentiviral vector shRNA‐Caveolin‐1 (sh‐Cav‐1‐LV). Cell dissociation assay and immunocytofluorescence were performed to assess keratinocyte dissociation, keratin retraction and Dsg3 endocytosis. Real‐time PCR was used to detect the mRNA level of Cav‐1, and western blot was used to determine the protein expression of Cav‐1, Dsg3, STAT3 and phosphorylated‐STAT3 (p‐STAT3). Results: The anti‐Dsg3 group showed more cell debris, increased keratin retraction, increased Dsg3 endocytosis, reduced Cav‐1 expression and co‐localization than the control group, while IL‐37 treatment neutralized all of these changes. Interestingly, Cav‐1 knockdown supressed the inhibitory effect of IL‐37 on keratinocyte dissociation and Dsg3 internalization. The protein expression of p‐STAT3 was increased in keratinocytes of the PV model but decreased by IL‐37. Re‐activation of the STAT3 pathway by colivelin supressed the inhibitory effect of IL‐37 on keratinocyte dissociation and Dsg3 internalization, along with upregulation of Cav‐1 and Dsg3. Conclusions: IL‐37 inhibited keratinocyte dissociation and Dsg3 endocytosis in an in vitro PV model through the upregulating Cav‐1 and inhibiting STAT3 pathway. [ABSTRACT FROM AUTHOR]

Prophylactic application of emollients has been an effective strategy against infant atopic dermatitis (AD); however, the difference of different emollients is unknown. We performed this network meta‐analysis to compare different emollients in preventing infant AD. A systematic search was performed in PubMed, EMBASE and Cochrane library to identify relevant studies from their inception through 28 February, 2022. We evaluated the quality of eligible studies using the Cochrane risk of bias assessment tool. Data analysis was performed using STATA 14.0. Eleven studies were included for data analysis. Direct meta‐analysis suggested that early application of emollients effectively prevented AD development in high‐risk infants (risk ratio [RR], 0.64; 95% confidence interval [CI], 0.47 to 0.88). Network meta‐analysis suggested that emollient emulsion might the better option for preventing infant AD development, with a surface under the cumulative ranking curve (SUCRA) of 82.6% for all populations, 78.0% for high‐risk populations and 79.2% for populations with food sensitization. Moreover, subjects receiving emollients more frequently experienced adverse events. Overall, early application of emollients is an effective strategy for preventing AD development in high‐risk infants and emollient emulsion may be the optimal type. Future study with well‐designed and large scale are warranted to validate our findings. [ABSTRACT FROM AUTHOR]